

## Odefsey - (200 mg; Eq 25 mg; Eq 25 mg , Tablet, Oral)

<b>Generic Name</b>	Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate	<b>Innovator</b>	Gilead
<b>Dosage</b>	200 mg; Eq 25 mg; Eq 25 mg , Tablet, Oral	<b>Branded US Sales</b>	More Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	More Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	ODEFSEY is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 35 kg: as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.